2014-18年中国一线抗逆转录病毒治疗失败HIV感染成人中多拉韦林交叉耐药的发生率
2014至2108年在中国五省4132例一线抗逆转录病毒治疗失败患者中行基因型耐药检测,按Stanford HIVdb 9.0判定耐药。多拉韦林及其他非核苷类逆转录酶抑制剂交叉耐药总发生率为69.5%,其中中、高水平耐药占56.4%。多拉韦林耐药与依非韦伦(r=0.720)和奈韦拉平(r=0.721)耐药高度相关。
要点
- 一线治疗失败者多拉韦林交叉耐药总发生率69.5%,中、高水平耐药占56.4%。
- 最常见的多拉韦林相关耐药突变为V106M(8.7%)、K101E(6.8%)和P225H(5.1%)。
- 与CRF01_AE相比,CRF07_BC(OR=0.595,95%CI=0.546-0.648)和CRF08_BC(OR=0.467,95%CI=0.407-0.536)的多拉韦林耐药风险更低。
核心结论
- 在中国,一线抗逆转录病毒治疗失败患者中多拉韦林交叉耐药发生率较高。
- 多拉韦林不应在未行基因型耐药检测的情况下盲目使用,且不推荐用于一线含非核苷类逆转录酶抑制剂方案治疗失败者。
研究设计与样本
- 2014至2108年,来自中国五省的4132例患者接受基因型耐药检测。
- 采用Stanford HIVdb算法9.0版评估耐药突变,低、中、高水平耐药均定义为耐药。
主要发现
- 多拉韦林及其他非核苷类逆转录酶抑制剂交叉耐药总发生率为69.5%,中、高水平耐药占56.4%。
- 多拉韦林耐药与依非韦伦耐药(r=0.720)和奈韦拉平耐药(r=0.721)高度相关,与依曲韦林耐药(r=0.637)和利匹韦林耐药(r=0.692)中度相关。
- 最常见的多拉韦林相关耐药突变为V106M(8.7%)、K101E(6.8%)和P225H(5.1%);高水平耐药主要由Y188L(3.2%)和M230L(2.7%)导致。
- 与CRF01_AE相比,CRF07_BC(OR=0.595,95%CI=0.546-0.648)和CRF08_BC(OR=0.467,95%CI=0.407-0.536)的多拉韦林耐药风险更低;基因型A(OR=3.003,95%CI=1.806-4.991)和基因型B(OR=1.250,95%CI=1.021-1.531)的多拉韦林耐药风险更高。
- 与其他省份相比,新疆的多拉韦林耐药风险显著更低。
临床怎么用
- 作者认为,多拉韦林不应在未行基因型耐药检测的情况下盲目使用,且不推荐用于一线含非核苷类逆转录酶抑制剂方案治疗失败者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the prevalence and characteristics of doravirine resistance and cross-resistance in patients who failed first-line ART in China. METHODS: From 2014 to 2108, 4132 patients from five provinces were tested for drug resistance by genotypic resistance testing. Drug resistance mutations were assessed using the Stanford HIVdb algorithm Version 9.0. Sequences classified as having low-level, intermediate and high-level resistance were defined as having drug resistance. RESULTS: Overall, the prevalence of doravirine and other NNRTIs cross-resistance was 69.5%, with intermediate and high-level resistance accounting for 56.4%. Doravirine resistance highly correlated with efavirenz (r = 0.720) and nevirapine (r = 0.721) resistance and moderately correlated with etravirine (r = 0.637) and rilpivirine (r = 0.692) resistance. The most frequent doravirine-associated resistance mutations were V106M (8.7%), K101E (6.8%) and P225H (5.1%). High-level resistance was mainly due to Y188L (3.2%) and M230L (2.7%). There were significant differences between genotypes and provinces. Compared with CRF01_AE, CRF07_BC (OR = 0.595, 95% CI = 0.546-0.648) and CRF08_BC (OR = 0.467, 95% CI = 0.407-0.536) were associated with lower risks of doravirine resistance. Conversely, genotype A (OR = 3.003, 95% CI = 1.806-4.991) and genotype B (OR = 1.250, 95% CI = 1.021-1.531) were associated with higher risks of doravirine resistance. The risk of doravirine resistance was significantly lower in Xinjiang compared with other provinces. CONCLUSIONS: In China, the prevalence of doravirine cross-resistance among patients who have failed first-line ART is high. Therefore, doravirine should not be used blindly without genotypic resistance testing and is not recommended for people who have failed first-line NNRTI-based ART.
引用
- Sun Z, Lan Y, Liang S, et al. Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18. J Antimicrob Chemother. 2022. PMID: 35134966. doi:10.1093/jac/dkac016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。